Bryan Cox
Hoofd Techniek/Wetenschap/O&O bij TRISALUS LIFE SCIENCES, INC.
Vermogen: 860 891 $ op 30-04-2024
Profiel
Dr. Bryan F.
Cox is a Chief Scientific & Manufacturing Officer at TriSalus Life Sciences, Inc. and a Chief Executive Officer at Nephraegis Therapeutics, Inc.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 12-02-2024 | 86 696 ( 0.32% ) | 860 891 $ | 30-04-2024 |
Actieve functies van Bryan Cox
| Bedrijven | Functie | Begin |
|---|---|---|
| TRISALUS LIFE SCIENCES, INC. | Hoofd Techniek/Wetenschap/O&O | 10-08-2023 |
Nephraegis Therapeutics, Inc.
 Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics, Inc. is a biopharmaceutical company that focuses on developing a family of proprietary drug candidates to prevent and treat acute kidney injury (AKI). The company is based in Lake Forest, IL. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The CEO of the company is Bryan F. Cox. | Algemeen Directeur | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| TRISALUS LIFE SCIENCES, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Nephraegis Therapeutics, Inc.
Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics, Inc. is a biopharmaceutical company that focuses on developing a family of proprietary drug candidates to prevent and treat acute kidney injury (AKI). The company is based in Lake Forest, IL. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The CEO of the company is Bryan F. Cox. | Health Technology |